Researcher profile
Manuel Arrojo
Affiliations
Organizations
Amsterdam University Medical Centersauthorship · NLCentro de Investigación Biomédica en Red de Salud Mentalauthorship · ESComplejo Hospitalario Universitario de Santiagoauthorship · ESComplexo Hospitalario Universitario A Coruñaauthorship · ESHospital General Universitario Gregorio Marañónauthorship · ESInstituto de Investigación Sanitaria de Santiagoauthorship · ESServicio Gallego de Saludauthorship · ES
Public evidence
9 connected articles
Methylomic signature of current cannabis use in two first-episode psychosis cohorts.2025 · Europe PMCThe impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies.2024 · Europe PMCCannabis use and cognitive biases in people with first-episode psychosis and their siblings.2024 · Europe PMCThe Role of Social Deprivation and Cannabis Use in Explaining Variation in the Incidence of Psychotic Disorders: Findings From the EU-GEI Study.2024 · Europe PMCCannabis use as a potential mediator between childhood adversity and first-episode psychosis: results from the EU-GEI case-control study.2023 · Europe PMCThe association between reasons for first using cannabis, later pattern of use, and risk of first-episode psychosis: the EU-GEI case-control study.2023 · Europe PMCThe continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study.2021 · PubMed Central Open AccessSocial disadvantage, linguistic distance, ethnic minority status and first-episode psychosis: results from the EU-GEI case-control study.2021 · PubMed Central Open AccessThe contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study.2019 · PubMed Central Open Access
Matched by exact identifiers only. Profile data: Corpus/OpenAlex.